12 Month Price Forecast For MRKR
Distance to MRKR Price Forecasts
MRKR Price Momentum
๐ค Considering Marker Therapeutics (MRKR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 6:21 PM UTC
MRKR Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, MRKR has a bullish consensus with a median price target of $11.50 (ranging from $4.00 to $19.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.72, the median forecast implies a 568.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Aydin Huseynov at Ladenburg Thalmann, projecting a 1,004.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRKR Analyst Consensus
MRKR Price Target Range
Latest MRKR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRKR.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Oct 21, 2024 | Ladenburg Thalmann | Aydin Huseynov | Buy | Maintains | $19.00 |
Apr 30, 2024 | Ladenburg Thalmann | Aydin Huseynov | Buy | Initiates | $11.00 |
Feb 17, 2022 | Roth Capital | Tony Butler | Neutral | Downgrade | $1.00 |
Mar 25, 2021 | Piper Sandler | Overweight | Initiates | $0.00 | |
Mar 19, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
Mar 18, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
May 12, 2020 | Piper Sandler | Edward Tenthoff | Neutral | Downgrade | $2.50 |
Nov 13, 2019 | Piper Jaffray | Overweight | Maintains | $0.00 | |
Nov 13, 2019 | Janney Montgomery Scott | Buy | Maintains | $10.00 | |
Nov 13, 2019 | Piper Sandler | Overweight | Maintains | $6.00 | |
Nov 13, 2019 | Janney Capital | Buy | Maintains | $0.00 | |
Jul 3, 2019 | Oppenheimer | Outperform | Initiates | $0.00 | |
May 30, 2019 | Roth Capital | Buy | Initiates | $0.00 | |
Mar 29, 2019 | WBB Securities | Strong Buy | Upgrade | $0.00 | |
Mar 1, 2019 | Janney Montgomery Scott | Buy | Initiates | $0.00 | |
Mar 1, 2019 | Janney Capital | Buy | Initiates | $0.00 |
Stocks Similar to Marker Therapeutics Inc
The following stocks are similar to Marker Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Marker Therapeutics Inc (MRKR) Financial Data
Marker Therapeutics Inc has a market capitalization of $18.42M with a P/E ratio of -1.8x. The company generates $5.40M in trailing twelve-month revenue with a -179.7% profit margin.
Revenue growth is +647.7% quarter-over-quarter, while maintaining an operating margin of -124.6% and return on equity of -79.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Marker Therapeutics Inc (MRKR) Company Overview
About Marker Therapeutics Inc
Develops T cell-based immunotherapies for cancer.
The company focuses on creating and commercializing innovative immunotherapies that utilize tumor-specific T cells to target various cancers. Its revenue is generated through the commercialization of these therapies, which are aimed at treating hematological malignancies and solid tumors, as well as through potential partnerships and collaborations within the biotech industry.
Marker Therapeutics is currently in the clinical stage and is working on several promising therapies, including MT-401-OTS for acute myeloid leukemia and MT-601 for lymphoma and pancreatic cancer. The company's headquarters are in Houston, Texas, positioning it within a significant biotech hub.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Juan F. Vera M.D.
Country
United States
IPO Year
2018
Website
markertherapeutics.comMarker Therapeutics Inc (MRKR) Latest News & Analysis
The APOLLO study of MT-601 in relapsed lymphoma patients reported a 78% objective response rate, with 44.4% achieving complete response.
Strong efficacy results from the APOLLO study for MT-601 in relapsed lymphoma may boost investor confidence, indicating potential for market success and increased revenue for the company involved.
Strategic financing is being utilized to advance the Phase 1 APOLLO study of MT-601, targeting lymphoma patients who have relapsed post anti-CD19 CAR-T treatment.
Strategic financing indicates confidence in MT-601's potential, enhancing its value as a treatment for relapsed lymphoma, which could lead to increased market opportunities and investor returns.
Marker Therapeutics, Inc. (Nasdaq: MRKR) received a $9.5 million grant from CPRIT to support clinical trials of MT-601 for metastatic pancreatic cancer.
The $9.5 million grant for Marker Therapeutics' MT-601 indicates increased validation and funding for its cancer treatment, potentially boosting stock value and future growth prospects.
Marker Therapeutics, Inc. (Nasdaq: MRKR) will present at the Ladenburg Thalmann Virtual Oncology Symposium on December 12, 2024, focusing on its T cell-based immunotherapies.
Marker Therapeutics' participation in the oncology symposium could signal potential growth and innovation in its T cell therapies, impacting investor sentiment and stock performance.
Marker Therapeutics, Inc. (MRKR) will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024, focusing on its T cell-based immunotherapies for cancer.
Marker Therapeutics' upcoming presentation at a key industry summit may influence investor sentiment, showcasing potential advancements in its therapies and attracting interest or investment in the company.
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
3 months agoMarker Therapeutics has secured two grants from the NIH SBIR program to support clinical trials of its MT-601 therapy for lymphoma and metastatic pancreatic cancer.
NIH grants enhance Marker Therapeutics' financial stability and validate its MT-601 research, potentially increasing investor confidence and stock value.
Frequently Asked Questions About MRKR Stock
What is Marker Therapeutics Inc's (MRKR) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Marker Therapeutics Inc (MRKR) has a median price target of $11.50. The highest price target is $19.00 and the lowest is $4.00.
Is MRKR stock a good investment in 2025?
According to current analyst ratings, MRKR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MRKR stock?
Wall Street analysts predict MRKR stock could reach $11.50 in the next 12 months. This represents a 568.6% increase from the current price of $1.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Marker Therapeutics Inc's business model?
The company focuses on creating and commercializing innovative immunotherapies that utilize tumor-specific T cells to target various cancers. Its revenue is generated through the commercialization of these therapies, which are aimed at treating hematological malignancies and solid tumors, as well as through potential partnerships and collaborations within the biotech industry.
What is the highest forecasted price for MRKR Marker Therapeutics Inc?
The highest price target for MRKR is $19.00 from Aydin Huseynov at Ladenburg Thalmann, which represents a 1,004.7% increase from the current price of $1.72.
What is the lowest forecasted price for MRKR Marker Therapeutics Inc?
The lowest price target for MRKR is $4.00 from at , which represents a 132.6% increase from the current price of $1.72.
What is the overall MRKR consensus from analysts for Marker Therapeutics Inc?
The overall analyst consensus for MRKR is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are MRKR stock price projections?
Stock price projections, including those for Marker Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.